Product development, as well as backward integration for the manufacturing process, has enabled Aurobindo Pharma's healthy profitability despite consistent price erosion (albeit at reduced intensity).
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
Motilal Oswal Report
Motilal Oswal has reiterated its Buy rating on Aurobindo Pharma Ltd., setting a target price of Rs 1,430, implying an 18% upside from the current market price of Rs 1,208.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The brokerage expects robust growth across key segments, supported by strategic investments, policy tailwinds, and diversification into high-value businesses.
Motilal Oswal projects Aurobindo to deliver a CAGR of 9% in sales, 14% in Ebitda, and 21% in PAT over FY26–28, supported by margin expansion and reduced leverage.
EPS is expected to rise from Rs 62.4 in FY26E to Rs 91.2 in FY28E.
At the current valuation of 19.3x FY26E earnings, the stock trades at a discount to its growth prospects. The brokerage values Aurobindo Pharma at 16x forward earnings, maintaining its Buy call with a target price of Rs 1,430.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
